Delving into the Latest Updates on Lirilumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-KIR (1-7F9), Anti-KIR monoclonal antibody, Lirilumab (USAN/INN)

+ [8]

Target

KIR2DL1 x KIR2DL2 x KIR2DL3 x KIR2DS1 x KIR2DS2

Action

antagonists, inhibitors

Mechanism

KIR2DL1 antagonists(Killer cell immunoglobulin-like receptor 2DL1 antagonists), KIR2DL2 antagonists(Killer cell immunoglobulin-like receptor 2DL2 antagonists), KIR2DL3 antagonists(Killer cell immunoglobulin-like receptor 2DL3 antagonists)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Recurrent Squamous Cell Carcinoma of the Head and NeckBladder Cancer

Inactive Indication

Acute Myeloid LeukemiaAdvanced cancerAdvanced Malignant Solid Neoplasm+ [11]

Originator Organization

Innate Pharma SA

Active Organization

Ono Pharmaceutical Co., Ltd.

Bristol Myers Squibb Co.

Inactive Organization

Bristol-Myers Squibb International Corp.

Innate Pharma SA

License Organization

Innate Pharma SA

Novo Nordisk A/S

Bristol Myers Squibb Co.

+ [1]

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 1260L

Source: *****

Sequence Code 10125384H

Source: *****

Patients with muscle-invasive bladder cancer (MIBC) who can not receive cisplatin or refuse cisplatin therapy will receive nivolumab or nivolumab/lirilumab before a planned surgical procedure called a radical cystectomy (RC) to remove the bladder.
Nivolumab works by attaching to and blocking a molecule called Programmed Death-1 (PD-1). Lirilumab attaches to and blocks a group of molecules called Killer Cell Immunoglobulin-Like Receptor (KIR). PD-1 and KIR are proteins present mainly on immune system cells, and each controls part of the immune system by shutting it down. It is hoped that by binding to and inactivating these proteins, these drugs can enhance the body's ability to detect, attack and destroy cancer cells.
The purpose of this research study is to see whether nivolumab alone or combination of nivolumab and lirilumab given before surgery is effective in treating people who have bladder cancer, and to examine the side effects, good and bad, associated with nivolumab and lirilumab.

Start Date22 Mar 2019

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT03347123

/ TerminatedPhase 1/2

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)

The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.

Start Date21 Mar 2018

Sponsor / Collaborator

Incyte Corp.

NCT03341936

/ Active, not recruitingPhase 2IIT

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck

This research study is studying a combination of two immunotherapy drugs, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck.
The immunotherapy drugs involved in this study are:
* Nivolumab (Opdivo™)
* Lirilumab

Start Date15 Mar 2018

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

100 Clinical Results associated with Lirilumab

Login to view more data

100 Translational Medicine associated with Lirilumab

Login to view more data

100 Patents (Medical) associated with Lirilumab

Login to view more data

34

Literatures (Medical) associated with Lirilumab

06 Jan 2026·CLINICAL AND EXPERIMENTAL IMMUNOLOGY

CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A

Article

Author: Blunt, Matthew D ; Sayegh, Souraya ; Graham, Lara V ; Foxall, Russell B ; Khakoo, Salim I ; Cragg, Mark S ; Ashton-Key, Margaret ; Leandro, Maria ; Reddy, Venkat R

Abstract:

Autoreactive B cells that remain in lymphatic tissue after anti-CD20 antibody therapy are considered a major contributing factor to relapse in patients with autoimmune diseases. Natural killer (NK) cells contribute to the depletion of autoreactive B cells by anti-CD20 antibodies via antibody-dependent cellular cytotoxicity (ADCC). However, the impact of germinal centre–associated signals CD40 ligand (CD40L) and interleukin-4 (IL-4) on ADCC was unknown. This study used a combination of flow cytometry, immunohistochemistry, and ex vivo functional assays using peripheral blood mononuclear cells to investigate how CD40L and IL-4 affect NK cell–B cell interactions. CD40L and IL-4 significantly upregulate human leukocyte antigen (HLA)-E and total HLA Class I expression on the surface of B cells from healthy donors, as well as patients with rheumatoid arthritis and systemic lupus erythematosus. The upregulation of HLA-E and total HLA functions to inhibit B-cell depletion by NK cell–mediated ADCC induced by rituximab via NKG2A and killer cell immunoglobulin-like receptors (KIR). Moreover, B cells that have differentiated through the germinal centre have higher expression of HLA-E and total HLA compared with naive B cells and are more resistant to depletion by rituximab. In accordance with this, blockade of NKG2A and inhibitory KIRs by monalizumab and lirilumab, respectively, increased antibody-dependent cellular cytotoxicity against autologous B cells in vitro. Overall, this study identifies a novel mechanism of resistance of B cells to NK cell cytotoxicity and indicates that blockade of the HLA-E:NKG2A and HLA:KIR checkpoint axes could be beneficial for improving B-cell depletion in patients with autoimmune diseases.

01 Sep 2025·European Urology Open Science

Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment—A Systematic Review of Current Evidence

Review

Author: Liebl, Bruno ; Nahas, William Carlos ; Fradet, Vicent ; Toren, Paul ; Lopes, Roberto Iglesias ; Faris de Campos, Vinícius Daniel ; Branquinho Reis, Gabriel Baêta ; Shahrour, Walid ; de Almeida, Lucas Schenk ; Suartz, Caio Vinicius ; Mota, José Mauricio ; Lima Aguiar Melão, Bárbara Vieira ; Shabana, Walid ; Henry Sant'Anna, Pedro Vasconcelos ; Ribeiro-Filho, Leopoldo Alves ; de Lima, Richard Dobrucki

Background and objective:

Immune checkpoint inhibitors (ICIs), alone or with platinum-based chemotherapy, have increasingly been studied as neoadjuvant therapy for muscle-invasive bladder cancer (BC). We sought to evaluate the current evidence about neoadjuvant immunotherapy for BC.

Methods:

In this systematic review, conducted in October 2024, only prospective studies on neoadjuvant immunotherapy for BC were included. Extracted variables encompassed study design, clinical-pathological characteristics, perioperative outcomes, pathological complete response (pCR) rates, overall survival (OS), event-free survival, and immune-related (irAEs) and treatment-related (TRAEs) adverse events.

Key findings and limitations:

From 726 records, 35 studies met the inclusion criteria. The highest pCR rate observed was 54%, utilizing durvalumab. Perioperative chemoimmunotherapy with durvalumab plus cisplatin/gemcitabine showed greater OS than chemotherapy alone in the NIAGARA trial. The NEMIO trial achieved the highest 12-mo OS rate of 97%, using durvalumab in combination with tremelimumab and dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, followed by the AURA trial (95%) and the LCCC1520 trial (91%). At 24 mo, the NEBULA trial reported a 100% OS rate with three doses of atezolizumab, while PrECOG PrE0807 reached and OS rate of 89% with nivolumab and lirilumab. The highest rates of grade 3 and 4 irAEs were reported for nivolumab combined with ipilimumab (54%) and for durvalumab combined with tremelimumab (64%). The most common grade 3/4 irAEs were hepatitis (2-27%), kidney injury (2-100%), and skin rash (1.1-41%). Grade 3/4 TRAEs were comparable between the ICI and chemotherapy groups.

Conclusions and clinical implications:

Neoadjuvant immunotherapy for BC has shown promising efficacy and a manageable adverse event profile. However, financial toxicity, the absence of predictive biomarkers, and the risk of significant irAEs remain challenges.

Patient summary:

This study reviewed recent clinical trials that tested immunotherapy before surgery in patients with bladder cancer. The results suggest that a combination of immunotherapy and chemotherapy may improve outcomes and reduce the risk of cancer returning. These findings could help shape future treatment options for patients with muscle-invasive bladder cancer.

01 May 2025·Journal for ImmunoTherapy of Cancer

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial

Article

Author: Tam, Rachel ; Luke, Jason J ; Gupta, Akshita ; Lee, George ; Reilly, Tim ; Szabo, Peter ; Yao, David ; Dutta, Santanu ; Taube, Janis ; Bao, Riyue ; Massey, Ashish ; Bever, Katherine ; Neely, Jaclyn ; Hodi, F Stephen

Background:

ADVISE (ADaptiVe biomarker trial that InformS Evolution of therapy) (NCT03335540) was a biomarker-adapted feasibility clinical trial of immunohistochemistry (IHC) to inform combination immuno-oncology (I-O) treatment.

Methods:

To inform I-O combination selection, messenger RNA expression analyses from The Cancer Genome Atlas evaluated associations between programmed death 1/programmed death ligand 1 (PD-1/PD-L1) and other I-O-associated genes. Tumor tissue blocks of melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, and gastroesophageal junction/gastric cancer were stained by IHC to assess expression of CD8, colony-stimulating factor 1 receptor, glucocorticoid-induced tumor necrosis factor receptor (GITR), indoleamine 2,3-dioxygenase 1, lymphocyte-activation gene 3, NKp46, forkhead box P3, and PD-L1. These results facilitated an I-O treatment selection algorithm where patient biopsy results dictated allocation into combinations of nivolumab with cabiralizumab, urelumab, linrodostat mesylate, relatlimab, BMS-986156 (anti-GITR), lirilumab, ipilimumab, or irradiation. The primary endpoint was the proportion of patients with qualified baseline tumor biopsy specimens where decision-enabling biomarker analysis was completed within 12 business days to select an I-O combination therapy.

Results:

Correlation of PD-1/L1 and I-O-associated genes varied across the spectrum of T-cell-inflamed versus non-inflamed tumors; however, tumors with low/intermediate PD-L1 expression demonstrated distinct upregulation of immune markers grouped by cell type (T cell, macrophage, etc). IHC analyses of I-O naïve tumors corroborated these findings with distinct immune target upregulation in low-to-intermediate inflamed tumors and significant associations between IHC-detected markers and T-cell inflammation score across most markers. In the clinical trial, 20/23 (87%) of eligible patients were successfully allocated and started on treatment within the 12-day window, meeting the primary endpoint. The safety profile appeared to generally align with those reported for the individual combinations from other trials. No treatment responses occurred. Most patients were allocated to the cabiralizumab treatment arm.

Conclusions:

Actualization of a patient-specific I-O combination treatment selection strategy is feasible, however, determination of de novo integral biomarker thresholds of novel I-O targets to facilitate effective treatment of PD-1-refractory cancer remains fraught. These data emphasize the difficulty of integral biomarker development for I-O in translating from immunotherapy treatment-naïve biospecimens to the selection of patients in the PD-1-refractory state.

Trial registration number:

NCT03335540.

2

News (Medical) associated with Lirilumab

06 Oct 2021

·www.biospace.com

Natural Killer (NK) Cell Therapeutics Market: Cancer Segment to Offer Attractive Opportunities

Natural Killer (NK) Cell: Introduction Natural killer (NK) cells also known as K cells or killer cells. These are a type of white blood cells (lymphocyte) and a component of the innate immune system. Natural killer cells play an important role in the host rejection of virally infected cells and tumors. Natural killer cells are cytotoxic. Small granules in natural killer cell cytoplasm contain special proteins, such as proteases and perforin known as granzymes. Once the foreign cell reaches the proximity of the natural killer cell, the natural killer cells attack the foreign cells by releasing protein including perforin that forms stomas in the cell membrane of the target cell through which the associated molecules and granzymes can enter and then induces apoptosis. Natural killer cells are activated in response to macrophage-derived cytokines and interferons. Patient deficient in natural killer cells is highly prone to early phases of the herpes virus infection. Request Brochure of Report - Key Drivers of Global Natural Killer (NK) Cell Therapeutics Market The global natural killer (NK) cell therapeutics market is primarily driven by increase in usage of natural killer cells for the treatment of liver and infectious diseases across the globe. According to the Centers for Disease Control and Prevention, in the U.S., in 2016, deaths due to tuberculosis stood at 9,272, salmonella claimed 53,850 lives, Lyme disease caused 36,429 deaths, and 375 people died due to the meningococcal disease. The number of patient visits to physician with parasitic and infectious as the primary diagnosis was reported to be 15.5 million in the U.S. in the same year. Increase in patient population with infectious and liver diseases is a key driver of the global natural killer (NK) cell therapeutics market Rise in the awareness among the population about various immunotherapies and increase in research and development of bi-specific antibody for engaging natural killer cells to eliminate tumor cells are driving the global natural killer (NK) cell therapeutics market Request for Analysis of COVID-19 Impact on Natural Killer (NK) Cell Therapeutics Market – Natural Killer (NK) Cell Directed Antibodies Segment Held Major Share of Global Market Based on type, the global natural killer (NK) cell therapeutics market can be divided into natural killer (NK) cell therapies and natural killer (NK) cell directed antibodies Natural killer (NK) cell therapies segment can be further divided into CNDO-109, oNKord, natural killer cells, and others Natural killer (NK) cell directed antibodies segment can sub-divided into MOGAMULIZUMAB, Lirilumab, AFM13, NKTT 120, and others Natural killer (NK) cell directed antibodies segment accounted for a major market share in 2018. The dominance of the segment can be attributed to increase in the use of monoclonal antibodies (mAbs) for various diseases and easy availability of these drugs. Pre book Natural Killer (NK) Cell Therapeutics Market Report at Cancer Segment to Offer Attractive Opportunities In terms of application, the global natural killer (NK) cell therapeutics market can be classified into gastrointestinal diseases, immune-proliferative disorders, cancer, and others Cancer segment is expected to account for a major share of the global natural killer (NK) cell therapeutics market in 2027 The dominance of this segment can be attributed to the increase in prevalence rate of cancer across the globe Read More Information: Top of Form ReadR Key Players Operating in Global Market The global natural killer (NK) cell therapeutics market is highly consolidated with presence of few players accounting for the majority of the market share. Key players operating in the global natural killer (NK) cell therapeutics market are: Affimed Celgene Corporation Glycostem Nkarta Therapeutics Innate Pharma S.A Ziopharm Oncology, Inc. NantKwest NKT Therapeutics Inc. Fate Therapeutics Fortress Biotech Inc Browse more Market Reports: Breast Imaging Market: Early detection of lesions with the help of AI and ML has helped to improve clinical numbers. This phenomena is being further leveraged with advanced screening mammography, whereas this technique is gaining global recognition as one of the most effective methods for detecting early breast cancer. This explains why ionizing breast imaging dictates the highest revenue among all technologies in the breast imaging market. Centrifuge Market: The World Health Organization (WHO) announced a fresh set of laboratory biosafety guidelines that are associated with the novel coronavirus (COVID-19) for healthcare professionals. WHO continues to monitor developments and revise their recommendations, since coronavirus is limited, but rapidly growing in major economies. Specific manipulations in laboratories such as loading and unloading of sealed centrifuge cups, grinding, and blending may cause splashing of droplets and aerosols of potentially infectious materials. Hence, companies in the centrifuge market as well as lab professionals are notified about routine laboratory procedures to prevent further spread of COVID-19. Veterinary Endoscopes Market: A rise in pet population with gastrointestinal problem are more willing to undergo endoscopies surgeries and diagnosis at veterinary hospitals and clinic. This is expected to increase the number of endoscopy procedures thus propelling growth of the veterinary endoscopes market. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website:

AntibodyCell Therapy

27 Nov 2017

·www.biospace.com

Innate Tanked as Drug Combined With Bristol-Myers’ Opdivo Flopped in Study

While lirilumab was shown to be well-tolerated, it did not demonstrate efficacy in treating that patient population. Shares of Innate Pharma continue to fall following last week’s revelation that its drug lirilumab in combination with Opdivo is not an effective treatment for patients with squamous cell carcinoma of the head and neck. While lirilumab was shown to be well-tolerated, it did not demonstrate efficacy in treating that patient population. The two companies announced right before the Thanksgiving holiday that lirilumab in combination with Opdivo (nivolumab) “did not provide clear evidence of benefit to patients or an obvious development path.” Lirilumab is a fully human antibody directed against the inhibitory killer-cell immunoglobulin-like receptors (KIRs) expressed predominantly on circulating natural killer (NK) cells. Discussions are ongoing regarding next steps for the program. “Clearly this is disappointing, but we remain convinced, based on broad preclinical evidence, that NK cells play an important role in cancer immunosurveillance. Together with Bristol-Myers Squibb , our partner, we will further examine these data to better understand the results and explore whether other combinations should be investigated,” Mondher Mahjoubi , Innate’s chief executive officer, said in a statement. Shares of Innate plunged on the news, falling to $5.25 per share. This morning the stock continued to dip to $5.08 per share on the European exchange. BMS and Innate struck a licensing deal in 2011. BMS paid Innate $35 million upfront and the French company stood to gain up to $430 million in milestone and development payments. This failure marks the second disaster for lirilumab this year. In February, Innate and partner BMS said lirilumab failed as a single agent maintenance treatment in elderly patients with acute myeloid leukemia (AML) in first complete remission. The drug had been in Phase II development by BMS. Innate said it will continue to press forward with lirilumab at the American Society of Hematology meeting next month and discuss the Phase II failure. In its statement this morning, Innate noted that it believes the Phase II data supports the notion that “alternate dosing regimens, where KIR receptors are not permanently occupied and allow the interaction with their cognate ligands during maturation, could be worth exploring” in AML patients. Mahjoubi added that killer-cell immunoglobulin-like receptors, as opposed to NKG2A receptors, play a pivotal role in NK cell maturation. He said that maturation requires the “interaction between KIRs and their cognate MHC class I ligands and thus full occupancy of the receptor may lead to dysfunction of maturing NK cells.” That function represents an “additional challenge” in finding the right dosing regimen or appropriate combination partner, Mahjoubi added. So far this year, BMS and Innate have seen two failures of lirilumab in different indications. Lirilumab is being investigated in six trials sponsored by Bristol-Myers Squibb, across a range of solid and hematological cancer indications in combination with other agents, such as Opdivo.

Phase 2License out/inASH

100 Deals associated with Lirilumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10444	Lirilumab	-	DB11754

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 2	United States	Bristol Myers Squibb Co.	15 Mar 2018
Bladder Cancer	Phase 2	Spain	Bristol-Myers Squibb International Corp.	24 Jun 2017
Esophageal Carcinoma	Phase 2	Spain	Bristol-Myers Squibb International Corp.	24 Jun 2017
Metastatic melanoma	Phase 2	Spain	Bristol-Myers Squibb International Corp.	24 Jun 2017
Non-Small Cell Lung Cancer	Phase 2	Spain	Bristol-Myers Squibb International Corp.	24 Jun 2017
Rectal Diseases	Phase 2	Spain	Bristol-Myers Squibb International Corp.	24 Jun 2017
Uterine Cervical Cancer	Phase 2	Spain	Bristol-Myers Squibb International Corp.	24 Jun 2017
Squamous Cell Carcinoma of Head and Neck	Phase 2	Italy	Bristol-Myers Squibb International Corp.	26 Jul 2016
Leukemia	Phase 2	United States	Bristol Myers Squibb Co.	21 Mar 2016
Myelodysplastic Syndromes	Phase 2	United States	Bristol Myers Squibb Co.	21 Mar 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03532451 (PrECOG PrE0807, Pubmed \| Eur Urol Oncol)	Phase 1	Bladder Cancer Neoadjuvant	43	Nivolumab alone	mmjvmvzxhl(cwjoolmlxy) = qrpacnmwvn vdvrxytqyl (xhmgrdktfy ) View more	Positive	01 Aug 2024
				Nivolumab with lirilumab	mmjvmvzxhl(cwjoolmlxy) = djcujpzlqq vdvrxytqyl (xhmgrdktfy ) View more
NCT01714739 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm	337	Nivolumab+Lirilumab (Part 1/2 Liri 0.1 + Nivo 3)	tayhoidunr = sgfbgbalap ymejpnwarj (uxzawsjvbv, dbqvwgdpnd - yaryyfuujg) View more	-	02 Feb 2023
				Nivolumab+Lirilumab (Part 1/2: Liri 0.3 + Nivo 3)	tayhoidunr = ujajgitzeq ymejpnwarj (uxzawsjvbv, ftfxpnhflb - ggdevtjcmz) View more
NCT03341936 (CTgov)	Phase 2	Recurrent Squamous Cell Carcinoma of the Head and Neck	29	Nivolumab+Lirilumab	evcszjqzow = vzlgmgrncs zpluejzqse (piowjkhecb, ioqxwrnavb - qjyhwpucyi) View more	-	16 Jun 2022
NCT03532451 (PrE0807 \| PrECOG PrE0807, CTgov)	Phase 1	Muscle Invasive Bladder Carcinoma \| Bladder Cancer	43	nivolumab (Cohort 1: Nivolumab)	jorovtsbor = rlivizsbow fmsypakojy (izpofihehi, dgpplniqep - ezwptkxlhq) View more	-	01 Sep 2021
				Nivolumab+Lirilumab (Cohort 2: Nivolumab/Lirilumab)	jorovtsbor = zxssrkgzfy fmsypakojy (izpofihehi, gfjuyshbnh - kicxwmszao) View more
NCT03341936 (ASCO 12021 \| ASCO 22021) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck Adjuvant \| Neoadjuvant	29	nivolumab+lirilumab	xprlkpweis(lpccyeejhq) = sctduekdqo cnmzxyvtjs (xnlvfwxhdr, 48 - 84) View more	Positive	28 May 2021
NCT03532451 (PrE0807, ASCO 12021 \| ASCO 22021) Manual	Phase 1	Non-Muscle Invasive Bladder Neoplasms Neoadjuvant	43	Nivolumab	blnktradcu(ggjzvmvpgs) = jtwyxnhhrz heictseuxk (hvpduchnxh ) View more	Positive	20 May 2021
				Nivolumab+Lirilumab	blnktradcu(ggjzvmvpgs) = mlzmyyeclj heictseuxk (hvpduchnxh, 1.2 - 19.5) View more
NCT02481297 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia	7	Lirilumab+Rituximab (Cohort 1: Refractory/Relapsed After Prior Therapy)	oaihcdhwaw = ibgyiososo cmdetxgsyz (bgaoqwgaru, jdyhephnsg - vircrmkgtj) View more	-	26 May 2020
				Lirilumab+Rituximab (Cohort 2: Untreated With High-rRisk mMolecular Features)	oaihcdhwaw = buskplkwja cmdetxgsyz (bgaoqwgaru, tzvoiggzpq - pkajgulrjq) View more
NCT02599649 (CTgov)	Phase 2	Leukemia \| Myelodysplastic Syndromes	10	Lirilumab (Low or Intermediate-1 MDS Group - Lirilumab)	xyuhkpdipe = rdavhminml aqvwophazu (woumwkjwly, sqpxdirmrb - djpbnhqdtv) View more	-	06 Jan 2020
				Nivolumab+Lirilumab (Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab)	scbbvldgmu(tyyrssptkd) = hdklvegzub jlhbjixdny (kwvjkrkvfk, hkhdevrvmi - ciaoiuksnr) View more
NCT02399917 (CTgov)	Phase 2	Recurrent Acute Leukemia \| Acute Biphenotypic Leukemia \| Refractory acute myeloid leukemia	36	Lirilumab+Azacitidine (Phase 1b Lead-in Cohort 1)	kibvaghrlm = aygrndyfqb gfdlmxvokk (xsvjkthxym, yiwwuypgyp - oaymgmirdp) View more	-	24 Sep 2019
				Lirilumab+Azacitidine (Phase 1b Lead-in Cohort 2)	kibvaghrlm = agfbmrzntx gfdlmxvokk (xsvjkthxym, fipphhsmms - bithdufdmb) View more
NCT01687387 (EFFIKIR, CTgov)	Phase 2	Acute Myeloid Leukemia	152	IPH2102 at 1 mg/kg (IPH2102 at 1 mg/kg)	whenlyxoeg(cfhujssnad) = weybdfxicu vnacksnzbp (iokfaqabed, prxmzcxyzp - dfaorfseyv) View more	-	08 Feb 2019
				Placebo (normal saline solution)+IPH2102 at 0.1 mg/kg (IPH2102 at 0.1 mg/kg)	whenlyxoeg(cfhujssnad) = kmayjqpgsc vnacksnzbp (iokfaqabed, vcggrlgbic - cmpvyyonol) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Lirilumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation